- Differential Diagnosis
- Diseases
- Drugs
- More
-
- Try building your search one term at a time, and be as specific as you can! Search term example: "chronic cough".
- Do not enter multiple findings such as "anemia, chronic cough, weight loss, vomiting" all at the same time.
- After selecting your term from the search results a list of possible diagnoses will be generated. If the list is too long, you will be able to narrow it down by entering additional terms.
- Do not enter values such as "heart rhythm 110" or "sodium 125", instead use "tachycardia" or "hyponatremia".
Drug Information for Totect Kit (dexrazoxane) for injection, for intravenous infusion onlyInitial U.S. Approval: 2007 (TopoTarget USA): 2 DOSAGE AND ADMINISTRATION
- 1 INDICATIONS AND USAGE
- 2 DOSAGE AND ADMINISTRATION
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 7 DRUG INTERACTIONS
- 10 OVERDOSAGE
- 11 DESCRIPTION
- 14 CLINICAL STUDIES
- 15 REFERENCES
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- 17 PATIENT COUNSELING INFORMATION
- External Links Related to Totect Kit (dexrazoxane) for injection, for intravenous infusion onlyInitial U.S. Approval: 2007 (TopoTarget USA)
Vial contents must be mixed and diluted before use.
2.1 Recommended Dose
Totect® should be given once daily for 3 consecutive days. The first infusion should be initiated as soon as possible and within the first six hours after extravasation.
The individual dosage is based on calculation of the Body Surface Area (BSA) up to a maximum dose of 2000 mg (each on Day 1 and 2) and 1000 mg (Day 3), corresponding to a BSA of 2 m2.
The recommended dose is: Maximum daily dose: Day one: 1000 mg/m2 2000 mg Day two: 1000 mg/m2 2000 mg Day three: 500 mg/m2 1000 mg 2.2 Dose Modifications
The Totect® dose should be reduced by 50% in patients with creatinine clearance values < 40 mL/min.
2.3 Directions for Mixing and Final Dilution
Read this entire section carefully before mixing and diluting.
Aseptic technique should be used during preparation.
Caution must be exercised when handling Totect® and preparing the mixed solution. [see How Supplied/Storage and Handling (16)]
Totect® should not be mixed or administered with any other drug during the infusion.
Preparation of Totect®
Step 1. Each vial of Totect® (dexrazoxane for injection) (500 mg) must first be mixed with 50 mL of the enclosed diluent. The resultant solution contains 10 mg/mL. This resultant solution should be used immediately (within 2 hours) after preparation. It contains no antibacterial preservative.
Step 2. Withdraw the recommended dose from the solution containing 10 mg/mL as prepared in Step 1 and further dilute into an infusion bag containing 1000 mL 0.9% Sodium Chloride. In order to obtain the required dose more than one vial may be needed. Totect® must not be mixed with any other drugs.
The infusion bag should be used immediately after preparation. The product is stable for 4 hours from the time of preparation when stored below 25ºC (77ºF).
The solution of Totect® is slightly yellow.
Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit. Solutions containing a precipitate should be discarded. Vials are for single use only. Unused solution should be discarded.
2.4 Administration
Totect® should not be mixed or administered with any other drug during the infusion. Administer as an intravenous infusion over 1 to 2 hours at room temperature and normal light conditions in a large caliber vein in an extremity/area other than the one affected by the extravasation. Cooling procedures such as ice packs, if used, should be removed from the extravasation area at least 15 minutes before Totect® administration in order to allow sufficient blood flow to the area of extravasation. Treatment on Day 2 and Day 3 should start at the same hour (+/- 3 hours) as on the first day.
- Drug Information Provided by National Library of Medicine (NLM).